SLU-PP-332 dosing (preclinical regimens)
> Updated:
Human schedule
Controlled data on this compound are limited. The regimens below were gathered from public sources online (studies and protocols) and are given as a reference, not a usage plan.
SLU-PP-332 has been administered subcutaneously in reported use (reconstituted 5 mg vial); the figures below are generalized from descriptive community protocols, as no human clinical trials exist (all published data are in mice).
This is a concise reference to regimens described for adults; it is not an individual prescription.
SLU-PP-332 dosage is described very inconsistently across public sources, so the numbers below are consolidated into one reference range rather than another general description of the compound.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 250 mcg subcutaneously, once daily | Starting dose |
| Intermediate | 500 mcg – 1 mg subcutaneously, once daily | Increase if needed |
| Upper level | 1.5 mg subcutaneously, once daily | Maximum in this schedule |
Background on the molecule, its mechanism and primary sources is covered in the monograph.
Practical dosing and effect details
In Billon and colleagues' study (ACS Chemical Biology, 2023), SLU-PP-332 was given to mice intraperitoneally, and frequency, not a single dose, drove the outcome: daily administration activated a muscle transcriptional program resembling the one triggered by acute aerobic exercise and improved running endurance. The authors describe this effect as ERRα-dependent, meaning it traces to the ERRα receptor specifically rather than to a general action of the compound on muscle tissue. The data come from mice only.
The schedule on this page (250 mcg to start, up to 1.5 mg at the upper range, once daily) follows the same logic: in the study, the effect built up gradually over several days of regular daily dosing, not right after the first injection.
The 5 mg vial mentioned above is reconstituted specifically for daily doses of that size, so the packaging matches the schedule on this page.
This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.